Literature DB >> 9199639

Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.

M B Amin1, C L Corless, A A Renshaw, S K Tickoo, J Kubus, D S Schultz.   

Abstract

For more than two decades, papillary renal cell carcinoma has been recognized as a possible distinct clinicopathologic subtype of renal cell carcinoma (RCC). However, the histologic criteria for its diagnosis and the clinical outcome are still debated. In an attempt to clarify the diagnostic criteria and resolve issues pertaining to biologic potential, we have evaluated the histologic spectrum of 62 papillary RCCs and assessed significance of conventional pathologic prognostic parameters (Fuhrrman's nuclear grade [NG], pathologic stage [Robson and TNM], tumor size, multifocality, necrosis, and foam cells) and correlated these with outcome. The mean age of patients was 61.8 years (range 22-83), and males were more commonly affected (1.8:1). Grossly, most tumors were well circumscribed, averaged 6.7 cm in size (range 1.8-18), and were predominantly localized to the renal poles (polar vs. mid-renal, 3:1). Multifocality was a prominent feature (24 cases), and in three cases tumors were bilateral. Microscopically, papillary RCCs were predominantly papillary or tubulopapillary, often with a thick fibrous capsule, foam cells, necrosis, hemorrhage, and multifocality. Thirty-five percent of these tumors were low grade (NG I and II) and 65% high grade (NG III and IV). Sixteen of these tumors presented in a higher stage (stages III and IV), and the overall stage correlated with NG (chi 2, p = 0.009). Tumors were further distinguished by cytoplasmic features: eosinophilic (42%), basophilic (34%) and mixed (24%). Eosinophilic tumors were predominantly high grade, and basophilic tumors low grade (chi 2, p = 0.000). A mean follow-up of 57 months showed progression (metastasis, recurrence, or death due to disease) in 21%, whereas 63% were free of disease. Eleven percent died of unrelated causes, and 5% were lost to follow-up. Kaplan-Meier survival analysis showed that both high NG and stage were strongly associated with decreased survival (p = 0.0000 each), as were decreased foam cell (p = 0.0025) and vascular invasion (p = 0.0002). Comparison of 196 reported cases of papillary RCC, including the current series, with reported large series of conventional RCC indicates that papillary RCC usually presents at an early stage, and stage I (Robson) papillary RCC has better 5 year survival rates (87%-100%) than does RCC of the same stage (65-75%). The overall 5 years survival rate for papillary carcinoma (82-90%) was also higher than that of conventional RCC (44-54%). In a Cox proportional hazard regression model, TNM stage appeared to be the only significant variable (p = 0.0000, hazard ratio 10.1) in predicting outcome among papillary RCC. Based on this experience, we conclude that (a) papillary RCC is a malignant tumor, with a tendency to present at a lower stage, but with a distinct potential for progression and aggressive behavior; (b) stratification of these tumors according to cell type, amount of foam cells, presence or absence of vascular invasion, nuclear grade, and pathologic stage provides useful prognostic information; (c) the better 5-year survival rate of papillary RCC (overall and for stage I tumors) compared with that of conventional RCC suggests that it is a tumor with lower malignant potential. Thus, histologic subcategorization of a renal carcinoma as papillary RCC appears to have prognostic implications.

Entities:  

Mesh:

Year:  1997        PMID: 9199639     DOI: 10.1097/00000478-199706000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  37 in total

Review 1.  Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI?

Authors:  Robert S Lim; Trevor A Flood; Matthew D F McInnes; Luke T Lavallee; Nicola Schieda
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses.

Authors:  Aliaksei Chyhrai; Jimsgene Sanjmyatav; Mieczyslaw Gajda; Olaf Reichelt; Heiko Wunderlich; Thomas Steiner; Enis Tanović; Kerstin Junker
Journal:  World J Urol       Date:  2010-06       Impact factor: 4.226

Review 3.  Radiologic-pathologic correlations of intratumoral tissue components in the most common solid and cystic renal tumors. Pictorial review.

Authors:  Emilio Quaia; Rossana Bussani; Maria Cova; Roberto Pozzi Mucelli
Journal:  Eur Radiol       Date:  2005-03-08       Impact factor: 5.315

4.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 5.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

6.  Differentiating solid, non-macroscopic fat containing, enhancing renal masses using fast Fourier transform analysis of multiphase CT.

Authors:  Bino A Varghese; Frank Chen; Darryl H Hwang; Steven Y Cen; Inderbir S Gill; Vinay A Duddalwar
Journal:  Br J Radiol       Date:  2018-06-21       Impact factor: 3.039

Review 7.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

Review 8.  Review of renal cell carcinoma and its common subtypes in radiology.

Authors:  Gavin Low; Guan Huang; Winnie Fu; Zaahir Moloo; Safwat Girgis
Journal:  World J Radiol       Date:  2016-05-28

9.  Expression of osteopontin and CD44 molecule in papillary renal cell tumors.

Authors:  Koviljka Matusan; Gordana Dordevic; Vladimir Mozetic; Ksenija Lucin
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

10.  Primary renal carcinoid tumour with lung metastasis misdiagnosed as renal cell carcinoma.

Authors:  Nour Daboul; Dulabh Monga; Mark Bunker
Journal:  BMJ Case Rep       Date:  2016-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.